6.
Lin S, Chen Y, Lu S, Fann M, Liu C, Kao S
. Regulation of IGFBP-5 expression during tumourigenesis and differentiation of oral keratinocytes. J Pathol. 2002; 198(3):317-25.
DOI: 10.1002/path.1220.
View
7.
Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, Turley S
. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021; 21(11):704-717.
DOI: 10.1038/s41577-021-00540-z.
View
8.
Li H, Durbin R
. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60.
PMC: 2705234.
DOI: 10.1093/bioinformatics/btp324.
View
9.
Hanna G, Villa A, Nandi S, Shi R, ONeill A, Liu M
. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2023; 10(1):32-41.
PMC: 10654930.
DOI: 10.1001/jamaoncol.2023.4853.
View
10.
Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M
. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499.
PMC: 5931375.
DOI: 10.1038/nature22396.
View
11.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z
. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141.
PMC: 8454663.
DOI: 10.1016/j.xinn.2021.100141.
View
12.
Tovaru S, Costache M, Perlea P, Caramida M, Totan C, Warnakulasuriya S
. Oral leukoplakia: A clinicopathological study and malignant transformation. Oral Dis. 2022; 29(4):1454-1463.
DOI: 10.1111/odi.14123.
View
13.
Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H
. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756.
PMC: 6211645.
DOI: 10.1101/gr.239244.118.
View
14.
Peng D, Rodriguez B, Diao L, Chen L, Wang J, Byers L
. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 T cell exhaustion. Nat Commun. 2020; 11(1):4520.
PMC: 7481212.
DOI: 10.1038/s41467-020-18298-8.
View
15.
Harrington K, Ferris R, Blumenschein Jr G, Colevas A, Fayette J, Licitra L
. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017; 18(8):1104-1115.
PMC: 6461049.
DOI: 10.1016/S1470-2045(17)30421-7.
View
16.
Wang C, Sun D, Huang X, Wan C, Li Z, Han Y
. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biol. 2020; 21(1):198.
PMC: 7412809.
DOI: 10.1186/s13059-020-02116-x.
View
17.
Wang T, Sun S, Zeng X, Li J
. ICI-based therapies: A new strategy for oral potentially malignant disorders. Oral Oncol. 2023; 140:106388.
DOI: 10.1016/j.oraloncology.2023.106388.
View
18.
Wise-Draper T, Gulati S, Palackdharry S, Hinrichs B, Worden F, Old M
. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022; 28(7):1345-1352.
PMC: 8976828.
DOI: 10.1158/1078-0432.CCR-21-3351.
View
19.
Hao Y, Hao S, Andersen-Nissen E, Mauck 3rd W, Zheng S, Butler A
. Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13):3573-3587.e29.
PMC: 8238499.
DOI: 10.1016/j.cell.2021.04.048.
View
20.
Morad G, Helmink B, Sharma P, Wargo J
. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337.
PMC: 8767569.
DOI: 10.1016/j.cell.2021.09.020.
View